Business Context and Reporting Period
Paysign, Inc. (PAYS) is a vertically integrated provider of prepaid card products and processing services for corporate, consumer, and government applications. The company operates as a single reporting segment, managing the full lifecycle of prepaid cards including transaction processing, cardholder enrollment, and value loading. As of December 31, 2024, Paysign managed approximately 600 card programs with 7.3 million cardholders. The reporting period covers the fiscal year ended December 31, 2024.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenues | $58,384,552 | $47,274,162 |
| Gross Profit | $32,197,334 | $24,136,165 |
| Gross Margin | 55.1% | 51.1% |
| Operating Income | $1,021,508 | ($167,255) |
| Net Income | $3,815,907 | $6,458,727 |
| Net Margin | 6.5% | 13.7% |
| Adjusted EBITDA | $9,621,083 | $6,712,966 |
| Cash from Operations | $22,947,120 | $27,620,624 |
| Unrestricted Cash | $10,766,982 | $16,994,705 |
| Restricted Cash | $111,576,204 | $92,356,308 |
Note: Restricted cash consists of funds held for card product and pharma patient affordability programs.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 23.5% year-over-year, driven primarily by a 212.3% surge in Pharma industry revenue ($12.65M vs. $4.05M) and a 4.6% increase in Plasma industry revenue ($43.88M vs. $41.95M).
- Profitability: While operating income improved from a loss of $167k to a profit of $1.02M, Net Income declined 40.9% to $3.82M. This decline was largely due to the absence of a $4.59M valuation allowance release on deferred tax assets that benefited the 2023 results.
- Cost Structure: Cost of revenues rose 13.2% due to increased network fees, customer care expenses, and fraud charges. Operating expenses increased 28.3%, primarily driven by higher compensation costs and technology investments.
- Liquidity: Unrestricted cash decreased by $6.2M, attributed to timing differences in pass-through claim reimbursements within the patient affordability business.
Guidance, Outlook, and Risks
- Outlook: Management expects available cash and forecasted cash flows to sustain operations for the next 24 months. The company plans to continue investing in technology, sales, marketing, and cybersecurity in 2025.
- Recent Acquisition: On March 19, 2025, Paysign entered into an Asset Purchase Agreement to acquire substantially all assets of Gamma Innovation LLC. Consideration includes cash tranches and 2.5 million shares of restricted stock, with potential for an additional 500,000 shares based on performance targets.
- Legal Proceedings: A securities class action lawsuit was settled in April 2024 for $3.75M, fully covered by directors-and-officers insurance. Four stockholder derivative actions are pending settlement as of December 2024.
- Risks: Key risks include regulatory changes in the payments and healthcare industries, data security breaches, reliance on third-party banking partners, and concentration of credit risk (two pharma customers represented 32% of accounts receivable as of year-end).
Investor Verification Checklist
- Verify the sustainability of the 212% growth in Pharma revenue and the associated customer concentration risk.
- Confirm the final purchase accounting and valuation for the Gamma Innovation LLC acquisition.
- Monitor the status of the pending stockholder derivative action settlements.
- Assess the impact of rising fraud charges and network fees on future gross margins.
- Review the company's ability to maintain banking relationships given the high volume of restricted cash held at a single financial institution.